BR112018067602A2 - ambrisentan para uso no tratamento de insuficiência renal aguda - Google Patents

ambrisentan para uso no tratamento de insuficiência renal aguda

Info

Publication number
BR112018067602A2
BR112018067602A2 BR112018067602A BR112018067602A BR112018067602A2 BR 112018067602 A2 BR112018067602 A2 BR 112018067602A2 BR 112018067602 A BR112018067602 A BR 112018067602A BR 112018067602 A BR112018067602 A BR 112018067602A BR 112018067602 A2 BR112018067602 A2 BR 112018067602A2
Authority
BR
Brazil
Prior art keywords
ambrisentan
treatment
renal failure
acute renal
acute
Prior art date
Application number
BR112018067602A
Other languages
English (en)
Inventor
Navarro Iker
Khanna Satish
Original Assignee
Noorik Biopharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noorik Biopharmaceuticals Ag filed Critical Noorik Biopharmaceuticals Ag
Publication of BR112018067602A2 publication Critical patent/BR112018067602A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine

Abstract

a presente invenção refere-se a ambrisentan e formulações do mesmo para uso no tratamento e na prevenção de insuficiência renal aguda associada à vasoconstricção renal.
BR112018067602A 2016-03-18 2017-03-20 ambrisentan para uso no tratamento de insuficiência renal aguda BR112018067602A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662310221P 2016-03-18 2016-03-18
EP16166046.9A EP3235496A1 (en) 2016-04-19 2016-04-19 Treatment of acute renal failure
US201662437949P 2016-12-22 2016-12-22
PCT/EP2017/056476 WO2017158199A1 (en) 2016-03-18 2017-03-20 Ambrisentan for use in the treatment of acute renal failure

Publications (1)

Publication Number Publication Date
BR112018067602A2 true BR112018067602A2 (pt) 2019-01-08

Family

ID=55808404

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067602A BR112018067602A2 (pt) 2016-03-18 2017-03-20 ambrisentan para uso no tratamento de insuficiência renal aguda

Country Status (17)

Country Link
US (3) US10870021B2 (pt)
EP (3) EP3235496A1 (pt)
JP (1) JP7237362B2 (pt)
KR (1) KR20180121539A (pt)
CN (1) CN109069443A (pt)
AU (1) AU2017235618B2 (pt)
BR (1) BR112018067602A2 (pt)
CA (1) CA3015432A1 (pt)
CL (1) CL2018002638A1 (pt)
DK (1) DK3429566T3 (pt)
ES (1) ES2856960T3 (pt)
HK (1) HK1259616A1 (pt)
IL (1) IL261457B (pt)
MX (1) MX2018011222A (pt)
SG (1) SG11201808009SA (pt)
WO (1) WO2017158199A1 (pt)
ZA (1) ZA201805562B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3639827A1 (en) * 2018-10-19 2020-04-22 Noorik Biopharmaceuticals AG Use of ambrisentan for the treatment of portal hypertension and cirrhosis
WO2021219671A1 (en) * 2020-04-28 2021-11-04 Noorik Biopharmaceuticals Ag Treatment of pulmonary complications of coronavirus infections
US20230165856A1 (en) * 2020-04-29 2023-06-01 Astrazeneca Ab Dapagliflozin and ambrisentan for the prevention and treatment of covid-19

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
AU2008282773B8 (en) * 2007-07-31 2013-03-07 Gilead Sciences, Inc. Metabolites and derivatives of ambrisentan
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
CN104136038A (zh) * 2012-02-29 2014-11-05 东丽株式会社 体腔积液抑制剂
BR112015020788A2 (pt) * 2013-03-08 2017-10-10 Abbvie Inc métodos de tratamento da lesão renal aguda
CA2910601A1 (en) * 2013-04-26 2014-10-30 La Jolla Pharmaceutical Company Compositions and methods for treating renal failure
WO2015069839A1 (en) * 2013-11-06 2015-05-14 Gilead Sciences, Inc. Combination therapy for treating pulmonary hypertension

Also Published As

Publication number Publication date
JP7237362B2 (ja) 2023-03-13
IL261457A (en) 2018-10-31
EP3429566A1 (en) 2019-01-23
WO2017158199A1 (en) 2017-09-21
US20210046332A1 (en) 2021-02-18
AU2017235618B2 (en) 2021-02-25
JP2019515942A (ja) 2019-06-13
EP3878439A1 (en) 2021-09-15
EP3878439B1 (en) 2023-10-04
US20190083820A1 (en) 2019-03-21
CA3015432A1 (en) 2017-09-21
HK1259616A1 (zh) 2019-12-06
AU2017235618A1 (en) 2018-09-27
SG11201808009SA (en) 2018-10-30
NZ746140A (en) 2022-03-25
KR20180121539A (ko) 2018-11-07
MX2018011222A (es) 2019-01-10
CL2018002638A1 (es) 2019-01-18
US20230233454A1 (en) 2023-07-27
US10870021B2 (en) 2020-12-22
IL261457B (en) 2021-09-30
ES2856960T3 (es) 2021-09-28
ZA201805562B (en) 2019-06-26
EP3429566B1 (en) 2021-01-27
US11642307B2 (en) 2023-05-09
DK3429566T3 (da) 2021-03-29
CN109069443A (zh) 2018-12-21
EP3235496A1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
SV2017005426A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
CO2019001193A2 (es) Métodos y composiciones para el tratamiento de trastornos epilépticos
SV2018005610A (es) Derivados de oxopiridina sustituidos
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
BR112018072401A2 (pt) combinações de linagliptina e metformina
BR112015023207A2 (pt) uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
BR112019009172A2 (pt) formulações para radioterapia e diagnóstico por imagem.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
CO2017011295A2 (es) Piroglutamato de vortioxetina
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
BR112018067602A2 (pt) ambrisentan para uso no tratamento de insuficiência renal aguda
CL2018000403A1 (es) Compuestos para uso en aplicaciones antibacterianas.
BR112018005299A2 (pt) 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
UY36434A (es) Nuevas formas cristalinas de la sal de monosodio del foramsulfurón
BR112017012400A2 (pt) processo para fabricação de partículas de resinato de fenilefrina; partículas de resinato de fenilefrina e uso de partículas de resinato de fenilefrina em formulações farmacêuticas
AR114030A1 (es) Triterpenos pentacíclicos en el tratamiento de una patología oral-dental
BR112016011554A2 (pt) Uso de brometo para minimizar ou prevenir a indução de inanição relacionada ao estresse ou inanição relacionada à ansiedade em um animal durante, ou em conclusão de, uma prática de comercialização ou gestão

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]